RECRUITING

Role of the Immune Environment in Response to Therapy in Breast Cancer

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

Official Title

Role of the Immune Environment in Response to Therapy in Breast Cancer

Quick Facts

Study Start:2022-10-03
Study Completion:2032-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05396612

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Julia T. Lewandowski
CONTACT
215-662-2861
Julia.Lewandowski@Pennmedicine.upenn.edu
Jennifer Zhang, MD
CONTACT
215-615-6810
Jennifer.Zhang@Pennmedicine.upenn.edu

Principal Investigator

Jennifer Zhang, MD
PRINCIPAL_INVESTIGATOR
Abramson Cancer Center

Study Locations (Sites)

Abramson Cancer Center
Philadelphia, Pennsylvania, 19104
United States

Collaborators and Investigators

Sponsor: Abramson Cancer Center at Penn Medicine

  • Jennifer Zhang, MD, PRINCIPAL_INVESTIGATOR, Abramson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-10-03
Study Completion Date2032-12-31

Study Record Updates

Study Start Date2022-10-03
Study Completion Date2032-12-31

Terms related to this study

Keywords Provided by Researchers

  • Immune microenvironment

Additional Relevant MeSH Terms

  • Breast Cancer
  • ER Positive Breast Cancer
  • HER2-negative Breast Cancer
  • TNBC - Triple-Negative Breast Cancer